MIRXES-B (02629) has announced that on April 27, 2026, the company received a letter from the Stock Exchange outlining the following guidance for the resumption of trading in its shares: (i) Conduct an appropriate independent forensic investigation into advance payments, significant cash outflows occurring after December 31, 2025, and any other payments of a similar nature or that raise similar concerns; assess the impact on the company's business operations and financial position; announce the investigation findings; and implement appropriate remedial actions. (ii) Demonstrate that there are no reasonable regulatory concerns regarding the integrity, competence, and/or character of the group's management and/or any individuals with significant influence over the company's management and operations that could pose risks to investors and damage market confidence. (iii) Appoint an independent internal control advisor to conduct an independent internal control review and demonstrate that: (i) the material weaknesses identified leading to the trading halt have been rectified and all necessary remedial measures have been implemented; and (ii) the company's internal controls are adequate and effective for their purpose, enabling the company to comply with the Listing Rules in all material respects, including but not limited to financial reporting, disclosure and compliance for discloseable and connected transactions, and the disclosure of material information. (iv) Publish all outstanding financial results in accordance with the Listing Rules and address any audit qualifications. (v) Demonstrate that the company has complied with the requirements of Rule 13.24 of the Listing Rules. (vi) Disclose all material information to the market to enable shareholders and investors to assess the company's status. The company's shares will continue to be suspended from trading.